Deferred Pre-Emptive Switch from Calcineurin Inhibitor to Sirolimus Leads to Improvement in GFR and Expansion of T Regulatory Cell Population: A Randomized, Controlled Trial
Open Access
- 11 October 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (10) , e75591
Abstract
Measures to prevent chronic calcineurin inhibitor (CNI) toxicity have included limiting exposure by switching to sirolimus (SIR). SIR may favorably influence T regulator cell (Treg) population. This randomized controlled trial compares the effect of switching from CNI to SIR on glomerular filtration rate (GFR) and Treg frequency. In this prospective open label randomized trial, primary living donor kidney transplant recipients on CNI-based immunosuppression were randomized to continue CNI or switched to sirolimus 2 months after surgery; 29 were randomized to receive CNI and 31 to SIR. All patients received mycophenolate mofetil and steroids. The main outcome parameter was estimated GFR (eGFR) at 180 days. Treg population was estimated by flowcytometry. Baseline characteristics in the two groups were similar. Forty-eight patients completed the trial. At six months, patients in the SIR group had significantly higher eGFR as compared to those in the CNI group (88.94±11.78 vs 80.59±16.51 mL/min, p = 0.038). Patients on SIR had a 12 mL/min gain of eGFR of at the end of six months. Patients in the SIR group showed significant increase in Treg population at 30 days, which persisted till day 180. There was no difference in the adverse events in terms of number of acute rejection episodes, death, infections, proteinuria, lipid profile, blood pressure control and hematological parameters between the two groups. Four patients taking SIR developed enthesitis. No patient left the study or switched treatment because of adverse event. A deferred pre-emptive switch over from CNI to SIR safely improves renal function and Treg population at 6 months in living donor kidney transplant recipients. Registered in Clinical Trials Registry of India (CTRI/2011/091/000034)Keywords
This publication has 27 references indexed in Scilit:
- Reduced Exposure to Calcineurin Inhibitors in Renal TransplantationNew England Journal of Medicine, 2007
- Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6‐Month Course of SteroidsAmerican Journal of Transplantation, 2007
- The janus face of immunosuppression – de novo malignancy after renal transplantation: the experience of the Transplantation Center MunichKidney International, 2007
- Complete Avoidance of Calcineurin Inhibitors in Renal Transplantation: A Randomized Trial Comparing Sirolimus and TacrolimusAmerican Journal of Transplantation, 2006
- Sirolimus with Neoral Versus Mycophenolate Mofetil with Neoral is Associated with Decreased Renal Allograft SurvivalAmerican Journal of Transplantation, 2004
- Late Calcineurin Inhibitor Withdrawal as a Strategy to Prevent Graft Loss in Patients with Suboptimal Kidney Transplant FunctionAmerican Journal of Nephrology, 2004
- The Natural History of Chronic Allograft NephropathyNew England Journal of Medicine, 2003
- Comparison of Sirolimus vs. Mycophenolate Mofetil on Surgical Complications and Wound Healing in Adult Kidney TransplantationAmerican Journal of Transplantation, 2003
- LONG-TERM IMPROVEMENT IN RENAL FUNCTION AFTER CYCLOSPORINE REDUCTION IN RENAL TRANSPLANT RECIPIENTS WITH HISTOLOGICALLY PROVEN CHRONIC CYCLOSPORINE NEPHROPATHYTransplantation, 1998
- A Randomized Clinical Trial of Cyclosporine in Cadaveric Renal TransplantationNew England Journal of Medicine, 1986